Dynavax DVAX Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Dynavax DVAX

DVAX 10.33

+0.2%

3:06 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	9/26/2018 11:19:51 AM
	Read Replies (2) of 184

ESMO late breaker (melanoma, PD-1 naive) title out, and it's as generic as can be. Report should include 15 patients in addition to results from ASCO.... Poster Discussion session - Melanoma Date 20.10.2018 Time 14:45 - 16:05 Moderators Jean Jacques Grob (Marseille, FR) Georgina V. Long (North Sydney, AU) Susana Puig Sarda (Barcelona, ES) Poster Discussion session LBA45 - Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy Presentation Number LBA45 Lecture Time 14:45 - 14:45 Speakers Georgina V. Long (North Sydney, AU)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next